L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy

被引:392
作者
Oudit, GY
Sun, H
Trivieri, MG
Koch, SE
Dawood, F
Ackerley, C
Yazdanpanah, M
Wilson, GJ
Schwartz, A
Liu, PP
Backx, PH [1 ]
机构
[1] Univ Toronto, Dept Med, Heart Stroke Richard Lewar Ctr Excellence, Toronto, ON M5S 3E2, Canada
[2] Univ Toronto, Dept Physiol, Heart Stroke Richard Lewar Ctr Excellence, Toronto, ON M5S 3E2, Canada
[3] Hosp Sick Children, Dept Pathol, Toronto, ON M5G 1X8, Canada
[4] Univ Cincinnati, Med Ctr, CVRC, Inst Mol Phamracol & Biophys, Cincinnati, OH 45267 USA
[5] Univ Hlth Network, Div Cardiol, Toronto, ON M5G 2C4, Canada
关键词
D O I
10.1038/nm920
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Under conditions of iron overload, which are now reaching epidemic proportions worldwide, iron-overload cardiomyopathy is the most important prognostic factor in patient survival. We hypothesize that in iron-overload disorders, iron accumulation in the heart depends on ferrous iron (Fe2+) permeation through the L-type voltage-dependent Ca2+ channel (LVDCC), a promiscuous divalent cation transporter. Iron overload in mice was associated with increased mortality, systolic and diastolic dysfunction, bradycardia, hypotension, increased myocardial fibrosis and elevated oxidative stress. Treatment with LVDCC blockers (CCBs; amlodipine and verapamil) at therapeutic levels inhibited the LVDCC current in cardiomyocytes, attenuated myocardial iron accumulation and oxidative stress, improved survival, prevented hypotension and preserved heart structure and function. Consistent with the role of LVDCCs in myocardial iron uptake, iron-overloaded transgenic mice with cardiac-specific overexpression of the LVDCC alpha(1)-subunit had twofold higher myocardial iron and oxidative stress levels, as well as greater impairment in cardiac function, compared with littermate controls; LVDCC blockade was again protective. Our results indicate that cardiac LVDCCs are key transporters of iron into cardiomyocytes under iron-overloaded conditions, and potentially represent a new therapeutic target to reduce the cardiovascular burden from iron overload.
引用
收藏
页码:1187 / 1194
页数:8
相关论文
共 65 条
[1]   Calcium-antagonist drugs [J].
Abernethy, DR ;
Schwartz, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (19) :1447-1457
[2]   Medical progress: Disorders of iron metabolism [J].
Andrews, NC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (26) :1986-1995
[3]   Metal transporters and disease [J].
Andrews, NC .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (02) :181-186
[4]   Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease -: The ENCORE I study (Evaluation of nifedipine and cerivastatin on recovery of coronary endothelial function) [J].
Azancot, I ;
Balbi, M ;
Bonnier, JJRM ;
Desmet, W ;
Diederich, KW ;
Drexel, H ;
Dubois-Rande, J ;
Etbel, R ;
Ribeiro, VD ;
Glogar, H ;
Hanrath, P ;
Hess, OM ;
Heyer, G ;
Hugenholtz, PG ;
Lafont, A ;
Lüscher, TF .
CIRCULATION, 2003, 107 (03) :422-428
[5]   Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease [J].
Ballas, SK .
SEMINARS IN HEMATOLOGY, 2001, 38 (01) :30-36
[6]   Hemochromatosis: The genetic disorder of the twenty-first century [J].
Barton, JC ;
Bertoli, LF .
NATURE MEDICINE, 1996, 2 (04) :394-395
[7]   EFFICACY OF DEFEROXAMINE IN PREVENTING COMPLICATIONS OF IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR [J].
BRITTENHAM, GM ;
GRIFFITH, PM ;
NIENHUIS, AW ;
MCLAREN, CE ;
YOUNG, NS ;
TUCKER, EE ;
ALLEN, CJ ;
FARRELL, DE ;
HARRIS, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (09) :567-573
[8]   IRON IN HEART - ETIOLOGY AND CLINICAL SIGNIFICANCE [J].
BUJA, LM ;
ROBERTS, WC .
AMERICAN JOURNAL OF MEDICINE, 1971, 51 (02) :209-&
[9]   Amlodipine Bioequivalence study: Quantification by liquid chromatography coupled to tandem mass spectrometry [J].
Carvalho, M ;
Oliveira, CH ;
Mendes, GD ;
Sucupira, M ;
Moraes, MEA ;
De Nucci, G .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2001, 22 (09) :383-390
[10]   Structure and regulation of voltage-gated Ca2+ channels [J].
Catterall, WA .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 2000, 16 :521-555